Navigation Links
Epilepsy drug dosage linked to specific birth defects

In a world first, new Australian medical research has given pregnant women with epilepsy new hope of reducing their chance of having a baby with physical birth defects.

According to research published in the September 2013 issue of Neurology, the medical journal of the American Academy of Neurology, epilepsy experts at The Royal Melbourne Hospital have discovered a link between high doses of common epilepsy drug valproate and the increased risk of having a baby with spina bifida or hypospadias.

Royal Melbourne Hospital epilepsy specialist and Head of the Department of Medicine at The University of Melbourne, Professor Terry O'Brien, said there was increasing concern among clinicians, patients and their families about the risk to the developing fetus of mothers taking valproate.

"For many women on epilepsy medication, the desire to start a family can be fraught with fear that they could have a baby with a range of disabilities or malformations," Professor O'Brien said.

"Previous studies have shown a strong relationship between the dose of valproate taken and the risk of the child having a birth defect. However, for many women valproate is the only drug that will help control their seizures.

"Through our research, we now know that by reducing the dose taken in the first trimester of pregnancy, the risk of having a baby with spina bifida or hypospadias will be greatly reduced."

Spina bifida is a birth defect of the spine and spinal cord, which occurs in utero in the first three months of pregnancy and cannot be cured. Hypospadias is a birth defect of the penis but can be treated with surgery.

Professor O'Brien added other birth defects such as cleft palates and heart defects were still common irrespective of the drug dosage given to pregnant women.

The research data was extracted from the Australian Pregnancy Register (APR), based at The Royal Melbourne Hospital.

The APR has the data of more than 1700 women with epilepsy who have been or are currently pregnant, and is the world's most comprehensive pregnancy epilepsy database. Since its inception in 1999, the APR has gathered data that has been used to change epilepsy prescribing practices worldwide.

Founder of the APR and RMH Epilepsy specialist, Professor Frank Vajda AM, said the findings were statistically significant to make a real difference to the lives of women with epilepsy and their families.

"We always knew that epilepsy drugs were responsible for the high level of fetal malformations but we never knew how much dosage played a role until recently," Professor Vajda said.

"The present findings for spina bifida are clinically significant, as 80 per cent of all instances of spina bifida in the APR were associated with valproate exposure.

"However, since the collection of data for the APR started, we have noted that valproate was being taken less often by pregnant women and in lower dosages.

"This evidence now tells us that by using valproate in the lowest dose that can control severe seizures may reduce the hazard of one of the most devastating birth defects."


Contact: Melea Tarabay
Melbourne Health

Related biology news :

1. Evidence of familial vulnerability for epilepsy and psychosis
2. Study raises questions about use of anti-epilepsy drugs in newborns
3. New model synapse could shed light on disorders such as epilepsy and anxiety
4. University of Minnesota engineering researchers discover new non-invasive method for diagnosing epilepsy
5. All in the family: A genetic link between epilepsy and migraine
6. Cats and humans suffer from similar forms of epilepsy
7. Dysfunction in cerebellar Calcium channel causes motor disorders and epilepsy
8. Lower dosage CT-guided lung biopsy protocol maintains quality, minimizes exposure
9. AcelRx Pharmaceuticals Receives First U.S. Patent for Small-Volume Oral Transmucosal Dosage Forms
10. Optimal vitamin D dosage for infants uncertain
11. Exposure to antibiotics linked to severity of allergic asthma: UBC research
Post Your Comments:
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at . 2016 ...
(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer and recently ... have entered into a multiyear collaboration to identify and characterize novel CRISPR-Cas nucleases. ... for gene editing across all applications. , Under the terms of the agreement, ...
(Date:10/11/2017)... N.C. (PRWEB) , ... October 11, 2017 , ... ... ARCS® Foundation President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, ... ( ASTER Labs ), Inc. has been selected for membership in ARCS ...
(Date:10/11/2017)... a leading provider of patient support solutions, has announced the ... which will launch this week. The VMS CNEs will address ... enhance the patient care experience by delivering peer-to-peer education programs ... to help women who have been diagnosed and are being ... ...
(Date:10/10/2017)... , ... October 10, 2017 , ... San Diego-based team ... its corporate rebranding initiative announced today. The bold new look is part of ... the company moves into a significant growth period. , It will also expand its ...
Breaking Biology Technology: